Status:

ACTIVE_NOT_RECRUITING

PET Scan in Planning Treatment in Patients Undergoing Combination Chemotherapy For Stage IA or Stage IIA Hodgkin Lymphoma

Lead Sponsor:

University College, London

Collaborating Sponsors:

The Christie NHS Foundation Trust

Conditions:

Lymphoma

Eligibility:

All Genders

16-75 years

Phase:

PHASE3

Brief Summary

RATIONALE: A PET scan may help doctors learn how the cancer responded to combination chemotherapy and whether radiation therapy is also required. PURPOSE: This randomized phase III trial is studying ...

Detailed Description

OBJECTIVES: * Determine whether patients with stage IA or IIA Hodgkin lymphoma who have a negative fludeoxyglucose F 18 positron emission tomography (FDG-PET) imaging after 3 courses of chemotherapy ...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Histologically confirmed Hodgkin Lymphoma
  • Stage IA or IIA disease
  • No stage IA Hodgkin lymphoma with no clinical or CT evidence of disease after diagnostic biopsy
  • Above the diaphragm with no mediastinal bulk, defined as maximum transverse diameter of mediastinal mass
  • Internal thoracic diameter at level of D5/6 interspace \> 0.33
  • Bulky disease at other sites, defined as nodal mass with transverse diameter ≥ 10 cm allowed
  • PATIENT CHARACTERISTICS:
  • Not pregnant or nursing
  • Fertile patients must use effective contraception during and for ≥ 6 months
  • No prior malignancy except appropriately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix
  • No severe underlying illness considered to make the trial therapy hazardous (i.e., severe heart disease or lung fibrosis)
  • Willing to travel to the nearest PET scan center
  • Able to comply with protocol follow-up arrangements
  • PRIOR CONCURRENT THERAPY:
  • No prior treatment for Hodgkin lymphoma
  • No contraindications to chemotherapy or radiotherapy

Exclusion

    Key Trial Info

    Start Date :

    July 1 2003

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    December 1 2028

    Estimated Enrollment :

    602 Patients enrolled

    Trial Details

    Trial ID

    NCT00943423

    Start Date

    July 1 2003

    End Date

    December 1 2028

    Last Update

    November 30 2023

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Christie Hospital

    Manchester, England, United Kingdom, M20 4BX

    PET Scan in Planning Treatment in Patients Undergoing Combination Chemotherapy For Stage IA or Stage IIA Hodgkin Lymphoma | DecenTrialz